Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-biologics-start-next-project-on-the-cbl-b-target-5028